Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.50
Bid: 297.50
Ask: 300.00
Change: -6.00 (-1.98%)
Spread: 2.50 (0.84%)
Open: 313.00
High: 313.50
Low: 296.50
Prev. Close: 302.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Interest in Shares

13 Mar 2008 12:26

Oxford Biomedica PLC13 March 2008 For Immediate Release 13 March 2008 Oxford BioMedica plc ("the Company") Directors' Interest in Shares and Share Options Oxford BioMedica (OXB:L) The Company today announced that on 13 March 2008 thefollowing awards under the Oxford BioMedica plc Long Term Incentive Plan (LTIP)were made to six executive directors. LTIP: Total shares Percentage of number of over which issued shares shares options are under option awarded held (note 1) Alan Kingsman 1,291,871 2,605,404 0.49%Susan Kingsman 565,640 1,643,331 0.31%Michael McDonald 1,017,542 3,087,843 0.57%Andrew Wood 977,533 2,384,974 0.44%Peter Nolan 771,400 1,612,355 0.30%Nick Woolf 788,582 2,434,867 0.45% Note 1: The total shares over which options are held (share options grantedbetween April 2001 and September 2006 and LTIPs awarded since March 2007)following the awards described above. The share price on which the awards were calculated was 22.5p (the closing priceon the day preceding the awards). The LTIP awards are nil-cost options. The LTIPawards are subject to a three year holding period, and are exercisable on thethird anniversary of the award, subject to the satisfaction of a TotalShareholder Return (TSR) performance condition described below. No awards will be released at the testing date for less than median performanceof Oxford BioMedica TSR compared to a comparator group made up of 20 companiesfrom the biotechnology and healthcare sectors. Median performance will result inrelease of 25% of the shares. Upper quartile performance (i.e. greater than 75thpercentile performance) will result in release of 100% of the shares, withstraight line release between these points. If the performance conditions arenot satisfied or partially satisfied at the end of the holding period, the LTIPaward or the balance of the award (as appropriate) not released shall lapse.There will be no re-testing of the performance conditions. Andrew Wood Company Secretary, Oxford BioMedica plc 13 March 2008 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Dec 20181:16 pmRNSDirector Dealings / Market Share Purchase
6th Dec 20184:11 pmRNSAxovant FDA meeting feedback
3rd Dec 20189:53 amRNSTotal Voting Rights
3rd Dec 20187:00 amRNSLonger term Kymriah efficacy and safety data
23rd Nov 201810:41 amRNSDirector Dealings
23rd Nov 20187:00 amRNSOxford Biomedica form digital framework initiative
9th Nov 20187:00 amRNSBlock listing application
1st Nov 20182:41 pmRNSTotal Voting Rights
25th Oct 20187:00 amRNSAxovant Doses First Patient with AXO-Lenti-PD
22nd Oct 20184:39 pmRNSDirector Dealings / Market Share Purchase
5th Oct 20187:00 amRNSDetails of alliance with Orchard Therapeutics
1st Oct 20189:41 amRNSTotal Voting Rights
24th Sep 201812:20 pmRNSDirector/PDMR Shareholding
20th Sep 201810:57 amEQSHardman & Co Research: Oxford BioMedica (OXB): Partnering strategy delivering profitability
13th Sep 20187:00 amRNSOxford BioMedica Interim Results
13th Sep 20187:00 amRNSOxford BioMedica further capacity expansion
3rd Sep 20189:18 amRNSTotal Voting Rights
28th Aug 20187:00 amRNSKymriah® receives European Commission Approval
22nd Aug 201811:58 amRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSRNS notice of results OXB
14th Aug 20187:15 amEQSHardman & Co Research: Oxford BioMedica (OXB): Risk-sharing in cystic fibrosis gene-therapy
13th Aug 201810:55 amRNSDirector/PDMR Shareholding
13th Aug 201810:48 amRNSDirector/PDMR Shareholding
10th Aug 201811:39 amRNSPDMR Dealings / Market Share Sale
10th Aug 201811:36 amRNSDirector Dealings / Market Share Sale and Purchase
8th Aug 20182:45 pmRNSShare Options and LTIPs Granted
6th Aug 20187:02 amRNSPartnership for Cystic Fibrosis Gene Therapy
1st Aug 20189:53 amRNSTotal Voting Rights
23rd Jul 201812:54 pmRNSDirector Dealings / Market Share Purchase
2nd Jul 201810:25 amRNSDirectorate Change
2nd Jul 20189:47 amRNSTotal Voting Rights
29th Jun 20181:37 pmRNSKymriah receives positive CHMP opinion
25th Jun 20185:19 pmRNSHoldings in Company
22nd Jun 201812:05 pmRNSConfirmation of change of Auditor
22nd Jun 201812:03 pmRNSDirector Dealings / Market Share Purchase
21st Jun 20185:52 pmRNSHoldings in Company
14th Jun 20189:51 amEQSHardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression
6th Jun 20187:00 amRNSOXB and Axovant Sciences Licence Agreement
4th Jun 20186:08 pmRNSDirectorate Change
1st Jun 20189:24 amRNSBlock Listing Return
1st Jun 20189:19 amRNSTotal Voting Rights
30th May 20184:23 pmRNSHoldings in Company
29th May 20181:21 pmRNSResult of General Meeting
29th May 20181:21 pmRNSResult of AGM
23rd May 20181:40 pmRNSDirector Dealings / Market Share Purchase
4th May 20187:00 amRNSProposed Share Capital Consolidation
2nd May 20187:00 amRNSKymriah receives FDA approval for DLBCL
1st May 20189:37 amRNSTotal Voting Rights
26th Apr 20183:33 pmRNSHolding(s) in Company
26th Apr 20187:30 amRNS2017 Annual Report and Accounts & AGM Notification

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.